Table 2.
Baseline characteristics
| Characteristic | All (n = 60) | Group A SNS/Placebo (n = 30) | Group B Placebo/SNS (n = 30) | P | |
|---|---|---|---|---|---|
| Age | |||||
| Median (Range), year | 50.5(32–75) | 53.5 (35–74) | 49.0 (32–75) | 0.57 | |
| < 50 years | 28(46.7%) | 12 | 16 | 0.30 | |
| ≥ 50 years | 32 (53.3%) | 18 | 14 | ||
| Marital Status | 0.75 | ||||
| Married | 58 (96.7%) | 29 | 29 | ||
| Divorced | 0 (0.0%) | 0 | 0 | ||
| Single | 2 (3.3%) | 1 | 1 | ||
| Widowed | 0 (0.0%) | 0 | 0 | ||
| Profession | 0.90 | ||||
| Mental labour | 44(73.3%) | 21 | 23 | ||
| Manual labour | 4 (6.7%) | 2 | 2 | ||
| Retired | 11 (18.3%) | 7 | 5 | ||
| Pathological classification | 0.64 | ||||
| Luminal A | 29 (48.3%) | 12 | 17 | ||
| Luminal B | 16 (26.7%) | 9 | 7 | ||
| Her-2 | 8 (13.3%) | 5 | 3 | ||
| TNBC | 7 (11.7%) | 4 | 3 | ||
| Histological grade | 0.36 | ||||
| 1 | 9 (15.0%) | 4 | 5 | ||
| 2 | 40 (66.7%) | 18 | 22 | ||
| 3 | 11(18.3%) | 7 | 4 | ||
| TNM stage | 0.41 | ||||
| I | 33 (55.0%) | 19 | 14 | ||
| II | 19 31.7%) | 7 | 14 | ||
| III | 8 (13.3%) | 5 | 3 | ||
| Tumor size | 0.59 | ||||
| < 2 cm | 30(50.0%) | 14 | 16 | ||
| 2–5 cm | 21 (35.0%) | 11 | 10 | ||
| ≥ 5 cm | 9 (15.0%) | 5 | 4 | ||
| Number of metastatic lymph nodes | 1.00 | ||||
| 0 | 27(45.0%) | 12 | 15 | ||
| 1–3 | 31 (51.7%) | 17 | 14 | ||
| ≥ 4 | 2 (3.3%) | 1 | 1 | ||
| Tumor distant metastasis | ns | ||||
| Presence | 0 (0.0%) | 0 | 0 | ||
| Absence | 60(100.0%) | 30 | 30 | ||
| Surgical approach | 0.58 | ||||
| Total mastectomy | 40(66.7%) | 21 | 19 | ||
| Breast-conserving surgery | 20 (33.3%) | 9 | 11 | ||
| Prior radiotherapy | 1.00 | ||||
| Use | 38(63.3%) | 19 | 19 | ||
| Unuse | 22 (36.7%) | 11 | 11 | ||
| Prior chemotherapy | 1.00 | ||||
| Use | 30 (50.0%) | 15 | 15 | ||
| Unuse | 30 (50.0%) | 15 | 15 | ||
| Current/prior endocrinotherapy | |||||
| SERM | 0.12 | ||||
| Use | 24(40.0%) | 18 | 12 | ||
| Unuse | 36 (60.0%) | 12 | 18 | ||
| AI | 0.44 | ||||
| Use | 33 (55.0%) | 15 | 18 | ||
| Unuse | 27 (45.0%) | 15 | 12 | ||
| OFS | 0.69 | ||||
| Use | 7(11.7%) | 4 | 3 | ||
| Unuse | 53(88.3%) | 26 | 27 | ||
| SERD | 0.75 | ||||
| Use | 2 (3.3%) | 1 | 1 | ||
| Unuse | 58 (96.7%) | 29 | 29 | ||
| Depression status | |||||
| Mild | 31(51.7%) | 15 | 16 | 0.80 | |
| Moderate | 29(48.7%) | 15 | 14 | ||
SERM Selective estrogen receptor modulators, AI aromatase inhibitors, OFS Ovarian function suppression, SERD Selective estrogen receptor degraders